Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial
Authors
Qingqing Cai (ORCID: https://orcid.org/0000-0001-9875-2419)
Yingxian Liu (ORCID: https://orcid.org/0000-0003-1155-7130)
Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial
Qingqing Cai, Yingxian Liu, Tsao‐Cheng Huang, Yi Cao et al.
Citations
3 citations
Journal
BMC Medicine
Topics
Head and Neck Cancer Studies
Field-Weighted Citation Impact (FWCI)
5.54
article
Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial
Qingqing Cai, Yingxian Liu, Tsao‐Cheng Huang, Yi Cao, Lixia Lu, Ning Su, Zhihua Li, Panpan Liu, Yuchen Zhang, Lirong Li, Fang Yu, Xicheng Wang, Xiaopeng Tian, Yi Xia, Qihua Zou, Y.C. Lai, Hao Wu
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
BMC MedicineVol. 23(1)
Institutions
Sun Yat-sen University (CN), Sun Yat-sen Memorial Hospital (CN), Sun Yat-sen University Cancer Center (CN)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial — Qingqing Cai, Yingxian Liu, et al. · BMC Medicine (2025) | TGRS Research Map | TGRS